首页> 外文期刊>Journal of Drug Delivery >Calcium Alginate-Neusilin US2 Nanocomposite Microbeads for Oral Sustained Drug Delivery of Poor Water Soluble Drug Aceclofenac Sodium
【24h】

Calcium Alginate-Neusilin US2 Nanocomposite Microbeads for Oral Sustained Drug Delivery of Poor Water Soluble Drug Aceclofenac Sodium

机译:海藻酸钙-Neusilin US2纳米复合微珠,用于不良水溶性药物醋氯芬酸钠的口服持续药物递送

获取原文
           

摘要

The aim of the present study was to formulate and investigate the calcium alginate- (CA-) Neusilin US2 nanocomposite microbeads containing preconcentrate of aceclofenac sodium (ACF-Na) liquid microemulsion (L-ME) for enhancement of oral bioavailability. The preconcentrate L-ME is prepared by using Labrafac PG, Labrasol, and Span 80 as oil, surfactant, and cosurfactant, respectively. The solid CA nanocomposite microbeads of L-ME prepared by microemulsification internal gelation technique using sodium alginate (SA) gelling agent, Neusilin US2 as adsorbent, and calcium chloride as crosslinking agent. L-ME has good thermodynamic stability; globule size was found to be 32.4 nm with polydispersity index 0.219 and −6.32 mV zeta potential. No significant interactions of excipients, drug in the formulations observed by FT-IR, DSC and XPRD. The concentration of SA and Neusilin US2 influences the flow properties, mean particle size, mechanical strength, drug entrapment efficiency, and percentage of drug release. All the formulations show minimum drug release in simulated gastric fluid (SGF) pH 1.2 for initial 2 h, maximum drug release in pH 6.8 phosphate buffer solution (PBS) at 6 h, followed by sustaining in simulated intestinal fluid (SIF) of pH 7.4 up to 12 h. The interaction of SA with Neusilin US2 creates a thick thixotropic gel network structure which acts as barrier to control the release of drug in the alkaline pH environment. Neusilin US2 is a novel filler used to convert L-ME into solid nanocomposite microbeads to enhance dissolution rate of poor water soluble drugs sustaining the drug release for prolonged period of time.
机译:本研究的目的是配制和研究藻酸钙-(CA-)Neusilin US2纳米复合微珠,其中含有醋氯芬酸钠(ACF-Na)液态微乳(L-ME)的预浓缩液,以增强口服生物利用度。通过分别使用Labrafac PG,Labrasol和Span 80作为油,表面活性剂和助表面活性剂来制备预浓缩液L-ME。通过微乳化内部胶凝技术,使用藻酸钠(SA)胶凝剂,Neusilin US2作为吸附剂和氯化钙作为交联剂,制备了L-ME的固体CA纳米复合微珠。 L-ME具有良好的热力学稳定性;发现小球尺寸为32.4 nm,多分散指数为0.219,-ζ电位为-6.32 mV。 FT-IR,DSC和XPRD观察到制剂中的赋形剂,药物之间无显着相互作用。 SA和Neusilin US2的浓度会影响流动性能,平均粒径,机械强度,药物截留效率和药物释放百分比。所有制剂在初始2?h时在模拟胃液(SGF)pH 1.2中显示最小的药物释放,在6?h时在pH 6.8磷酸盐缓冲溶液(PBS)中最大的药物释放,然后在pH 7.4的模拟肠液(SIF)中维持高达12 h。 SA与Neusilin US2的相互作用产生了浓稠的触变性凝胶网络结构,该结构充当了在碱性pH环境中控制药物释放的屏障。 Neusilin US2是一种新型填料,用于将L-ME转化为固体纳米复合微珠,以提高不良水溶性药物的溶出率,从而延长药物的释放时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号